IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients

•A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted. The healthcare system in Iran, like...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2021-10, Vol.99, p.107998-107998, Article 107998
Hauptverfasser:	Tabarsi, Payam, Hashemian, Seyed Mohammad Reza, Bauhofer, Artur, Savadkoohi, Ali Amir, Ghadimi, Somayeh, Haseli, Sara, Dastan, Farzaneh
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-inflammatory agents Computed tomography Coronaviruses COVID-19 COVID-19 - therapy Cytokine storm Cytokines Dexamethasone Enrichment Health services Humans Hyperinflammation IgM-enriched immunoglobulin Immunoglobulin M Immunoglobulin M - therapeutic use Immunoglobulins Inflammation Intravenous immunoglobulin (IVIG) Iran Lung - pathology Mortality Patients SARS-CoV-2 Sepsis Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!